PARIS, Feb 10 (Reuters) - Shares in biotech company Novacyt , which is launching a coronavirus test, surged on Monday to extend previous big gains made this year on investor hopes it could win regulatory approval for its coronavirus test product.
Novacyt shares were up around 14% in early session trading in Paris. The stock has risen by around 300% so far in 2020.
Last week, Novacyt said it had applied for emergency approval from the U.S. Food & Drug Administration (FDA) as it races to roll out a product that tests for the coronavirus, which has killed more than 900 people. (Reporting by Sudip Kar-Gupta; Editing by Edmund Blair)